• 1
    Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. The Free Press, New York, 1991.
  • 2
    Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 1994; 51: 819.
  • 3
    Ettigi P, Meyerhoff AS, Chirban JT, Jacobs RJ, Wilson RR. The quality of life and employment in panic disorder. J. Nerv. Ment. Dis. 1997; 185: 368372.
  • 4
    Eguchi M, Noda Y, Nakano Y et al. Quality of life and social role functioning in Japanese patients with panic disorder. J. Nerv. Ment. Dis. 2005; 193: 686689.
  • 5
    Delgado MR, Olsson A, Phelps EA. Extending animal models of fear conditioning to humans. Biol. Psychol. 2006; 73: 3948.
  • 6
    Salkovskis PM, Clark DM, Hackman A. Treatment of panic attacks using cognitive therapy without exposure or breathing retraining. Behav. Res. Ther. 1991; 29: 161166.
  • 7
    Marks IM, Swinson RP, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br. J. Psychiatry 1993; 162: 776787.
  • 8
    Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 83: 25292536.
  • 9
    Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. Br. J. Psychiatry 2006; 188: 305312.
  • 10
    Martinsen EW, Olsen T, Tonset E, Nyland KE, Aarre TF. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up. J. Clin. Psychiatry. 1998; 59: 437442;quiz 443.
  • 11
    Wade WA, Treat TA, Stuart GL. Transporting an empirically supported treatment for panic disorder to a service clinic setting: A benchmarking strategy. J. Consult. Clin. Psychol. 1998; 66: 231239.
  • 12
    Hahlweg K, Fiegenbaum W, Frank M, Schroeder B, Von Witzleben I. Short- and long-term effectiveness of an empirically supported treatment for agoraphobia. J. Consult. Clin. Psychol. 2001; 69: 375382.
  • 13
    Andrews G, Creamer M, Crino R, Hunt C, Lampe L, Page A. Panic disorder and agoraphobia. In: The Treatment of Anxiety Disordres. Clinicia's Guide and Patient Munuals, 2nd edn. Cambridge University Press, New York, 2002; 36147.
  • 14
    First MB, Spitzer RL, Gibbon M, Janet BW, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Press Inc., Washington, DC, 1997.
  • 15
    Van Balkom AJ, De Beurs E, Koele P, Lange A, Van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. J. Nerv. Ment. Dis. 1996; 184: 133135.
  • 16
    Westra HA, Stewart SH, Conrad BE. As-needed use of benzodiazepines in managing clinical anxiety: Incidence and implications. Curr. Pharm. Des. 2002; 8: 5974.
  • 17
    Shear MK, Brown TA, Barlow DH et al. Multicenter collaborative panic disorder severity scale. Am. J. Psychiatry 1997; 154: 15711575.
  • 18
    Yamamoto I, Nakano Y, Watanabe N et al. Cross-cultural evaluation of the Panic Disorder Severity Scale in Japan. Depress. Anxiety 2004; 20: 1722.
  • 19
    Marks IM. Behavioural Psychotherapy: Maudsley Pocket Book of Clinical Management. IOP Publishing, Bristol, 1986.
  • 20
    Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav. Res. Ther. 1979; 17: 263267.
  • 21
    Chambless DL, Caputo GC, Jasinm SE, Gracely EJ, Williams C. The Mobility Inventory for Agoraphobia. Behav. Res. Ther. 1985; 23: 3544.
  • 22
    Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: The body sensations questionnaire and the agoraphobic cognitions questionnaire. J. Consult. Clin. Psychol. 1984; 52: 10901097.
  • 23
    Derogaris LR. SCL-90-R. Administration, Scoring and Procedures Manual-II for the (Revised) Version and Other Instruments of the Psychopathology Rating Scale Series. Clinical Psychometric Research Inc, Towson, MD, 1992.
  • 24
    Furukawa TA, Nakanishi M, Sakurai A, Suzuki Y, Suzuki-Moor A, Hamanaka T. Effects of ethyl loflazepate in mood and neurosis-related disorders (ICD-10 JCM); Changes in SCL-90-R subscale scores. Jpn. J. Clin. Psychiatry 1996; 25: 233240 (in Japanese).
  • 25
    Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: A simple measure of impairment in functioning. Br. J. Psychiatry 2002; 180: 461464.
  • 26
    Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI): Professional Manual. Psychological Assessment Resources, Inc, Odessa, FL, 1992.
  • 27
    Shimonaka J. Report on the Japanese Version of the NEO PI-R. Tokyo Metropolitan Institute of Gerontology, Tokyo, 1996.
  • 28
    Yoshimura K, Ono Y, Nakamura K, Nathan JH, Suzuki K. Validation of the Japanese version of the NEO Five-Factor Inventory in a large community sample. Psychol. Rep. 2001; 88: 443449.
  • 29
    Perini SJ, Slade T, Andrews A. Generic effectiveness measures: Sensitivity to symptom change in anxiety disorders. J. Affect. Disord. 2006; 90: 123130.
  • 30
    Basoglu M, Marks IM, Swinson RP, Noshirvani H, O'Sullivan G, Kuch K. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J. Affect. Disord. 1994; 30: 123132.
  • 31
    Wardle J, Hayward P, Higgitt A, Stabl M, Blizard R, Gray J. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behav. Res. Ther. 1994; 32: 203215.
  • 32
    Michelson LK, Marchione K. Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis. J. Consult. Clin. Psychol. 1991; 59: 100114.